Visterra Obtains $13,000,000 Series A Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=58edd337-16d6-488f-8ec9-29ff59ab00db&Preview=1 -
Date
11/9/2012 -
Company Name
Visterra -
Mailing Address
One Kendall Square Cambridge, MA 02139 -
Company Description
Visterra, Inc. is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. The Company focuses on technologies that can interrogate how pathogens interact with human cells, a critical first step in the disease process. The company’s lead programs are focused on seasonal and pandemic influenza. -
Website
http://www.visterrainc.com -
Transaction Type
Venture Equity -
Transaction Amount
$13,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds will be used to further develop and validate Visterra’s technology platform and advance its proprietary infectious disease product pipeline. The company’s lead product candidate, VIS410, is a broad spectrum antibody for the prevention and treatment of both seasonal and pandemic influenza. -
M&A Terms
-
Venture Investor
Bill & Melinda Gates Foundation -
Venture Investor
Omega Funds
